UPDATE: Syndax Pharmaceuticals (SNDX) Tops Q4 EPS by 11c; Encore 601 Refractory Melanoma Cohort to Proceed to Second Stage of Phase 2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| (NASDAQ: SNDX) | Delayed: 13.43 +0.28 (2.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.15 | 52 Week High | $18.03 | |||
| Open | $13.06 | 52 Week Low | $8.97 | |||
| Day High | $13.48 | P/E | N/A | |||
| Day Low | $13.05 | EPS | $0.00 | |||
| Volume | 142,952 | |||||
